BioPharma Resources

Drug Trial Radar · NCT04818372

Dose Escalation and Expansion Study of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

A Phase I, Multiple Center, Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of CM313 in Subjects With Relapsed or Refractory Multiple Myeloma and Lymphoma

Last checked: Nov 19, 2026Latest source record: Nov 12, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

87

Planned (sponsor's estimate)

Start

Apr 26, 2021

Primary completion

Jan 2023

Study completion Apr 2023

Sponsor

Lead sponsor
Keymed Biosciences Co.LtdIndustry
Sponsor type
Industry
First posted
Mar 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, open-label, dose escalation and dose expansion, Phase 1 study to evaluate the safety, tolerability, PK and preliminary anti-tumor activity of CM313. The dose escalation part will determine the MTD of CM313 in subjects with relapsed and/or refractory multiple myeloma (RRMM) or lymphoma based on a modified 3+3 dose escalation design (an accelerated dose titration design followed by traditional 3+3 dose escalation design). The dose expansion part includes two cohorts. Cohort 1 will evaluate the safety and preliminary anti-tumor activity of CM313 in combination with Dexamethasone in subjects with RRMM. Cohort 2 will evaluate the safety and preliminary anti-tumor activity of CM313 in combination with Rd regimen (Lenalidomide/Dexamethasone) in subjects with RRMM or newly diagnosed MM (NDMM).

Conditions

  • Multiple Myeloma
  • Lymphoma

Interventions

  • CM313-Dose escalationDrug

    Subjects will receive a single dose of CM313 followed by a 3-week period for DLT observation. After that subjects will have 6 infusions at weekly intervals.

  • CM313Drug

    Subjects will have 8 infusions at weekly intervals, and then 8 infusions at bi-weekly intervals. After that CM313 will be given every 4 weeks until disease progression or unacceptable toxicity.

  • DexamethasoneDrug

    dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle

  • LenalidomideDrug

    25 mg/day lenalidomide 21 of 28 days cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose escalation: Number of Participants with a Dose-Limiting Toxicity (DLT)Time frame: Up to 21 days after the first dose
  2. Dose escalation and Dose expansion: Incidence, severity, and outcome of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0Time frame: Up to 30 days after the last dose of CM313 or until the start of subsequent anticancer therapy, if earlier
  3. Dose expansion: To evaluate the activity of CM313 in combination with Rd/Dexamethasone as assessed by overall response rate (ORR) in RRMM patientsTime frame: Up to 24 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Chao-Yang Hospital, Capital Medical University (West Branch)

    Beijing, Beijing Municipality, China · Recruiting

  • Beijing Chao-Yang Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.